NCT04389944View on ClinicalTrials.gov

Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19

NACompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)
Interventions
OTHER

convalescent plasma application to SARS-CoV-2 infected patients

In addition to standard of care, SARS-CoV-2 infected patients for whom blood group compatible convalescent plasma is available and who are willing to sign the informed consent receive convalescent plasma as follows: 200ml at enrolment and 200ml at 12-24 hours follow-up.

Trial Locations (1)

4031

Blutspendezentrum SRK beider Basel, University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT04389944 - Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19 | Biotech Hunter | Biotech Hunter